{"id":"NCT00761319","sponsor":"Alcon Research","briefTitle":"Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health","officialTitle":"An Evaluation of the Ocular Surface Health in Subjects Using TRAVATAN Z® Ophthalmic Solution Versus XALATAN® Ophthalmic Solution","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2009-09","completion":"2009-09","firstPosted":"2008-09-29","resultsPosted":"2012-04-23","lastUpdate":"2012-04-26"},"enrollment":705,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Open-angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)","otherNames":["TRAVATAN Z®"]},{"type":"DRUG","name":"Latanoprost ophthalmic solution 0.005% (XALATAN®)","otherNames":["XALATAN®"]}],"arms":[{"label":"Travoprost","type":"EXPERIMENTAL"},{"label":"Latanoprost","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.","primaryOutcome":{"measure":"Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score","timeFrame":"Day 0, Day 90","effectByArm":[{"arm":"Travoprost","deltaMin":-9.1,"sd":1},{"arm":"Latanoprost","deltaMin":-10.2,"sd":0.9}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":353},"commonTop":[]}}